AI Biologics firm Absci tie up with AstraZeneca on Cancer Drug Anglo-Swedish drugmaker AstraZeneca (AZN.L) has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci (ABSI.O) to design an antibody to fight cancer, Absci said in a statement on Sunday.
Absci's collaboration with AstraZeneca aims for a zero-shot generat